Who Paid My Doc
Exparel
Drug Pain Management
NDC 65250-266-09
General payments
$15,416,582
Research payments
$6,006,348
Through program year 2025, $15,416,582 in general payments and $6,006,348 in research payments were reported against Exparel (Pain Management).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $2,931,464 | 15,143 |
| 2025 | Research | $294,431 | 172 |
| 2024 | General | $2,523,037 | 12,983 |
| 2024 | Research | $292,921 | 37 |
| 2023 | General | $2,748,646 | 10,705 |
| 2022 | General | $3,490,283 | 10,725 |
| 2021 | General | $3,723,152 | 9,585 |
| 2021 | Research | $5,418,996 | 116 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 146 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
59,141 general · 325 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.